APOLLO: Personalized rehAbilitation PrOgram in aLLOgeneic Bone Marrow Transplantation
APOLLO
1 other identifier
observational
45
1 country
1
Brief Summary
People who undergo allogeneic bone marrow transplant for blood cancers receive the highest chemotherapy doses possible that humans can receive and still survive. As a result, they have devastating side effects during the procedure and for many years afterwards. Damage to organs and muscles cause long-lasting physical weakness and the psychological experience is severe enough to be termed 'post traumatic stress disorder' that also lasts for many years. These effects are worsened by the fact that most Canadians live several hours away from treatment and transplant centers, leaving them entirely on their own to manage these difficult long term effects. The APOLLO team will perform a qualitative study to learn the experiences of people undergoing allogeneic bone marrow transplant while they receive access to a supportive care computer 'app' and telephone support from nursing, exercise and nutrition experts. In this way, the APOLLO team will learn the most helpful type and timing of supportive care from those who know best.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Nov 2022
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 20, 2022
CompletedFirst Posted
Study publicly available on registry
October 14, 2022
CompletedStudy Start
First participant enrolled
November 20, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2025
CompletedSeptember 19, 2024
September 1, 2024
2.6 years
September 20, 2022
September 11, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Title: Acceptability of a multimodal supportive care
Description: Questionnaire to assess usefulness of a multimodal supportive care App that includes care navigation (nursing, exercise, nutrition)
1 year
Interventions
Supportive nursing, nutritional and physical activity with a handheld 'app'
Eligibility Criteria
individuals scheduled to undergo allogeneic transplantation
You may qualify if:
- eligible for allogeneic transplantation
You may not qualify if:
- none
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Alberta
Edmonton, Alberta, T6G 1C9, Canada
Related Publications (1)
Pituskin E, Foulkes S, Skow RJ, McMurtry T, Kruger C, Bates JE, Lamoureux D, Brandwein J, Lieuw E, Wu C, Zhu N, Wang P, Sawler D, Taparia M, Hamilton M, Comfort-Riddle T, Meyer T, Gyenes GT, Paterson I, Prado CM, Haykowsky MJ, Greiner JG, McNeely ML, Tandon P, Thompson RB. Rationale and design of APOLLO: a personalized rehAbilitation PrOgram in aLLOgeneic bone marrow transplantation. BMC Cancer. 2025 Jan 28;25(1):163. doi: 10.1186/s12885-025-13502-8.
PMID: 39875816DERIVED
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 20, 2022
First Posted
October 14, 2022
Study Start
November 20, 2022
Primary Completion
June 30, 2025
Study Completion
June 30, 2025
Last Updated
September 19, 2024
Record last verified: 2024-09